ATE484282T1 - Verwendung von trilostan oder keto-trilostan in kombination mit einem anti-oestrogen zur behandlung von hormon-abhängigen krankheiten. - Google Patents

Verwendung von trilostan oder keto-trilostan in kombination mit einem anti-oestrogen zur behandlung von hormon-abhängigen krankheiten.

Info

Publication number
ATE484282T1
ATE484282T1 AT00948147T AT00948147T ATE484282T1 AT E484282 T1 ATE484282 T1 AT E484282T1 AT 00948147 T AT00948147 T AT 00948147T AT 00948147 T AT00948147 T AT 00948147T AT E484282 T1 ATE484282 T1 AT E484282T1
Authority
AT
Austria
Prior art keywords
trilostane
compounds
hormone
oestrogen receptor
estrogen
Prior art date
Application number
AT00948147T
Other languages
English (en)
Inventor
George Margetts
John Puddefoot
Gavin Paul Vinson
Original Assignee
Stegram Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stegram Pharmaceuticals Ltd filed Critical Stegram Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE484282T1 publication Critical patent/ATE484282T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00948147T 2000-01-18 2000-07-25 Verwendung von trilostan oder keto-trilostan in kombination mit einem anti-oestrogen zur behandlung von hormon-abhängigen krankheiten. ATE484282T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0000984A GB2345851B (en) 2000-01-18 2000-01-18 A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
PCT/GB2000/002858 WO2001053321A2 (en) 2000-01-18 2000-07-25 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers

Publications (1)

Publication Number Publication Date
ATE484282T1 true ATE484282T1 (de) 2010-10-15

Family

ID=9883801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948147T ATE484282T1 (de) 2000-01-18 2000-07-25 Verwendung von trilostan oder keto-trilostan in kombination mit einem anti-oestrogen zur behandlung von hormon-abhängigen krankheiten.

Country Status (11)

Country Link
EP (1) EP1255553B1 (de)
JP (1) JP2003520803A (de)
AT (1) ATE484282T1 (de)
AU (1) AU785439B2 (de)
CA (1) CA2395481C (de)
DE (1) DE60045111D1 (de)
GB (1) GB2345851B (de)
IL (2) IL150768A0 (de)
NZ (1) NZ520350A (de)
WO (1) WO2001053321A2 (de)
ZA (1) ZA200206507B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
GB2421183A (en) * 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
SI1919290T1 (sl) 2005-07-12 2014-05-30 Ampio Pharmaceuticals, Inc. Postopki in proizvodi za zdravljenje bolezni
HUE028212T2 (en) 2009-06-22 2016-12-28 Ampio Pharmaceuticals Inc Procedure for treating diseases
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
FR3131285A1 (fr) 2021-12-23 2023-06-30 Kis Installation de distribution de boissons dans des recipients notamment de type canette

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5995300A (ja) * 1982-11-02 1984-06-01 スタ−リング・ドラッグ・インコ−ポレ−テッド コントロ−ルされた粒度の２−シアノ−４，５−エポキシ−３−オキソ−ステロイド類およびそれらの組成物
GB8404980D0 (en) * 1984-02-25 1984-03-28 Sterwin Ag Steroid compound
DE3720420A1 (de) * 1987-06-16 1988-12-29 Schering Ag Progesteronsynthesehemmer und antigestagene zur geburtseinleitung oder fuer den schwangerschaftsabbruch
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases

Also Published As

Publication number Publication date
WO2001053321A2 (en) 2001-07-26
JP2003520803A (ja) 2003-07-08
AU6171400A (en) 2001-07-31
NZ520350A (en) 2004-05-28
DE60045111D1 (de) 2010-11-25
IL150768A0 (en) 2003-02-12
WO2001053321A3 (en) 2002-02-28
CA2395481A1 (en) 2001-07-26
GB2345851A (en) 2000-07-26
ZA200206507B (en) 2005-01-13
AU785439B2 (en) 2007-05-31
CA2395481C (en) 2008-11-18
EP1255553A2 (de) 2002-11-13
IL150768A (en) 2007-10-31
GB0000984D0 (en) 2000-03-08
EP1255553B1 (de) 2010-10-13
GB2345851B (en) 2004-05-26

Similar Documents

Publication Publication Date Title
Roozendaal et al. Basolateral amygdala lesions block the memory‐enhancing effect of glucocorticoid administration in the dorsal hippocampus of rats
Isaacs The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis
ATE484282T1 (de) Verwendung von trilostan oder keto-trilostan in kombination mit einem anti-oestrogen zur behandlung von hormon-abhängigen krankheiten.
Richard Endocrine therapy for breast cancer
Williamson et al. Understanding hormone and hormone therapies' impact on the auditory system
Todorova Prevalence and etiology of the most common malignant tumours in dogs and cats
Arsovska et al. Thyroid disorder: treatment with acupuncture
Gouveia et al. Reduction of aggressive behaviour following hypothalamic deep brain stimulation: Involvement of 5-HT1A and testosterone
Swann Gonadal steroids regulate behavioral responses to pheromones by actions on a subdivision of the medial preoptic nucleus
Gupta Role of stress and hormones of the hypothalamic-pituitary-adrenal (HPA) Axis in aging
Chan et al. Mechanism of the regulation of the 1α, 25-dihydroxyvitamin D3 receptor in the rat jejunum by glucocorticoids
Luyck et al. Can electrical stimulation of the human bed nucleus of the stria terminalis reduce contextual anxiety? An unanswered question
Ross et al. The influence of lifestyle factors on cancer biology and treatment efficacy
Cho et al. Therapeutic effect of microcurrent therapy in a rat model of secondary lymphedema
Johnstone et al. The evolving landscape of stereotactic radiosurgery for localized vertebral metastases of the spine
Coleridge et al. Aorticopulmonary glomus tissue in the cat
Cihan Kemik Metastazı Tedavisinde Hedefleyici Radyoterapinin Eksternal Işın Radyoterapisi İle Eşzamanlı Kullanımı
Al-Marmadhi et al. Study the effect of allicin nanoparticles in thyroid activity in hyperthyroidism experimental induced female rats
van Steenbrugge et al. Hormonal and growth factor manipulation of human prostate cancer in the nude mouse model
Balanezhad et al. The effect of extremely low frequency electromagnetic field on angiogenesis
Joshi et al. 107. Progestin-dependent proteins in the human endometrium
Pal et al. Hormones in normal and abnormal human tissues
Stölting et al. Muscle Precursor Cells are safe for the treatment of urinary incontinence after surgery for prostate cancer
Nahed et al. A study on radiation energy of Pyramidal shape 1-Effect of housing within a Pyramid model on cancer growth and some blood parameters of mice
Prehn et al. Whipsaw cancer treatments: The role of hormesis in endocrine and immune therapies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties